Journals / Retina-Vitreus / 2011 / Cilt: 19 - Sayı: 4

Poor response to one dose intravitreal bevacizumab treatment for neovascular age-related macular degeneration

Yaş tip senil maküla dejenerasyonu tedavisinde tek doz intravitreal bevacizumab tedavisine olumsuz yanıt

Pages
237–240
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Studies with long term follow-up and larger sample size will be able to give us more precise results to predict the outcome of anti-VEGF treatments for neovascular AMD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate patients with poor response to one-dose intravitreal anti-VEGF treatment for neovascular age-related macular degeneration (AMD).
📊
Key Findings & Data:Materials and Methods: Sixty-seven eyes of 64 patients treated with intravitreal bevacizumab (IVB) for neovascular AMD were evaluated retrospectively.
💡
Conclusion & Impact:Studies with long term follow-up and larger sample size will be able to give us more precise results to predict the outcome of anti-VEGF treatments for neovascular AMD.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate patients with poor response to one-dose intravitreal anti-VEGF treatment for neovascular age-related macular degeneration (AMD). Materials and Methods: Sixty-seven eyes of 64 patients treated with intravitreal bevacizumab (IVB) for neovascular AMD were evaluated retrospectively. Best corrected visual acuity (BCVA), fundus photography, optical coherence tomography (OCT) results, and fluorescein angiography findings were reviewed. No improvement in BCVA were defined as poor response. Patients with poor response and good response to one dose IVB treatment were compared. Intragroup assessments were done by Wilcoxon, intergroup assessments were done with Mann-Whitney U tests. Results: Fifty-one percent of eyes had poor response (n=34). Pretreatment mean BCVA was significantly better in poor response group compared to good response group (p=0.012). Lesion area, lesion type, and OCT characteristics were not different between groups. Although statistically not significant, pigment epithelium detachment was more frequent in poor response group compared to good response group. (44%, 27%, respectively, p=0.151) Conclusion: Whether there is a criterion to predict the outcome of an anti-VEGF treatment for neovascular AMD is an important question among retina specialists. Although this study evaluates only the response for one dose IVB treatment, it shows the importance of pretreatment BCVA as a criterion. Studies with long term follow-up and larger sample size will be able to give us more precise results to predict the outcome of anti-VEGF treatments for neovascular AMD.

Özet

Amaç: Eksudatif tip senil maküla dejenerasyonu (SMD) tedavisinde tek doz intravitreal bevacizumab (İVB) uygulamasına olumsuz yanıt veren olguların değerlendirilmesi. Gereç ve Yöntem: Kliniğimizde eksudatif SMD tanısı ile tedavi edilen, subfoveal lezyonları olan ardışık 64 olgunun 67 gözü çalışmaya dahil edildi. Olguların İVB uygulaması öncesindeki ve 1. ay kontrollerindeki görme keskinlikleri (GK- logMAR), fundus muayeneleri, optik koherens tomografi (OKT) verileri ve flöresein anjiografi (FA) bulguları retrospekif olarak değerlendirildi. Olumsuz yanıt olarak görme keskinliğinde değişme olmaması veya azalma olması kabul edildi. Olumsuz yanıt alınan ve iyi yanıt alınan olgular karşılatırıldı. Grup içi değerlendirme için Wilcoxon, gruplar arası değerlendirme için Mann-Whitney U testleri kullanıldı. Bulgular: Gözlerin %51’inde olumsuz yanıt izlendi. Bu grupta anlamlı olarak tedavi öncesi görme keskinliği daha iyi idi (p=0.012). Gruplar arasında lezyon boyutu, lezyon tipi, OKT karakteristikleri arasında istatistiksel olarak anlamlı bir fark yoktu. Ancak olumsuz yanıt grubunda iyi yanıt grubuna göre OKT’de pigment epitel dekolmanı daha sık izlendi (sırasıyla %44, %27, p=0.151). Tartışma: Eksudatif tip SMD için uygulanan İVB tedavisine alınan yanıtın önceden tahmin edilmesini sağlayacak kriterlerin belirlenmesi günümüzde retina uzmanlarının cevabını aradıkları sorulardan biridir. Her ne kadar tek İVB enjeksiyonu sonrası yanıtlar değerlendirilmiş olsa da bu çalışmada, enjeksiyon öncesi görme keskinliğinin tedavi yanıtının önceden belirlenmesinde önemli bir kriter olduğu ortaya konmuştur. Uzun süreli takipler ve geniş olgu serileri ile daha detaylı sonuçlar elde edilebilecektir.

🔖

Cite This Article

ÖZMEN, M. C., ÖZDEK, Ş., HASANREİSOĞLU, B. (2011). Poor response to one dose intravitreal bevacizumab treatment for neovascular age-related macular degeneration. Retina-Vitreus, Cilt: 19 - Sayı: 4, 237–240. https://ajindex.com/articles/308075

References (11)

  1. Lux, A., Llacer H., Heussen F.M., et al.: Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol. 2007;91:1318-1322
  2. Rich, R.M., Rosenfeld P.J., Puliafito C.A., et al.: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511
  3. Barbazetto, I., Burdan A., Bressler N.M., et al.: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment TAP and VIP report No
  4. Arch Ophthalmol. 2003;121:1253-1268
  5. Brown, D.M., Kaiser P.K., Michels M., et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444
  6. Brown, D.M., Michels M., Kaiser,P.K. et al.: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65
  7. Rosenfeld, P.J., Brown D.M., Heier J.S., et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431
  8. Boyer, D.S., Antoszyk A.N., Awh C.C., et al.: Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246-252
  9. Abraham-Marin, M.L., Cortes-Luna C.F., Alvarez-Rivera G., et al.: Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2007;245:651-655
  10. Costa, R.A., R. Jorge, D. Calucci, et al.: Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006;47:4569-4578
  11. Lazic, R., Gabric N.: Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:68-73.